Daxor Corporation - Closed End Fund (DXR)
DXR moved a median of 0.00% 30 minutes after news, and +0.04% by the close. How DXR actually reacts to news — the realized, point-in-time move the market made, measured across 200 labeled events over the last three years with zero look-ahead.
DXR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 89 |
| 30-min | 0.00% | 50% | 119 |
| 60-min | 0.00% | 47% | 147 |
| to close | +0.04% | 51% | 188 |
| Middle 50% of DXR reactions | -0.61% to +1.45% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 200 |
Half of all Daxor Corporation - Closed End Fund news events land between -0.61% and +1.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DXR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DXR's baseline. Nothing else.
Recent DXR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 | Press release | GlobeNewswire | +0.68% | -0.39% | |
| Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 | Press release | GlobeNewswire | -1.14% | -3.90% | |
| Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 | Press release | GlobeNewswire | +0.29% | -0.10% | |
| Form 40-8F-2/A DAXOR CORP | SEC filing · Form 40-8F-2 | SEC EDGAR | -1.88% | -2.98% | |
| Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 | Press release | GlobeNewswire | — | -1.35% | |
| Form N-CEN/A DAXOR CORP For: Dec 31 | SEC filing · Form N-CEN | SEC EDGAR | -0.71% | -2.74% | |
| Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference | Press release | GlobeNewswire | +3.46% | -2.25% | |
| Form 40-8F-2/A DAXOR CORP | SEC filing · Form 40-8F-2 | SEC EDGAR | — | -2.19% | |
| Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter | Press release | GlobeNewswire | — | +8.13% | |
| Form N-CSR DAXOR CORP For: Jun 30 | SEC filing · Form N-CSR | SEC EDGAR | — | +8.13% | |
| Form N-PX DAXOR CORP For: Jun 30 | SEC filing · Form N-PX | SEC EDGAR | — | +1.81% | |
| Form NPORT-P DAXOR CORP For: Jun 30 | SEC filing · Form NPORT-P | SEC EDGAR | — | +8.13% | |
| Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas | Press release | GlobeNewswire | — | — | |
| Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas | Press release | GlobeNewswire | +0.00% | +2.19% | |
| Form 8-K DAXOR CORP For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | — | -3.91% | |
| Form 40-8F-2/A DAXOR CORP | SEC filing · Form 40-8F-2 | SEC EDGAR | +0.00% | +3.83% | |
| Form DEF 14A DAXOR CORP For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | — | +3.52% | |
| Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor | Press release | GlobeNewswire | +0.00% | +3.65% | |
| Form NT NPORT-P DAXOR CORP For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +3.65% | |
| Form 40-8F-2/A DAXOR CORP | SEC filing · Form 40-8F-2 | SEC EDGAR | — | +0.00% | |
| Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis | Press release | GlobeNewswire | — | +4.72% | |
| Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center | Press release | GlobeNewswire | -0.11% | -1.04% | |
| Form N-CEN/A DAXOR CORP For: Dec 31 | SEC filing · Form N-CEN | SEC EDGAR | — | -0.56% | |
| Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 | Press release | GlobeNewswire | — | -3.72% | |
| Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions | Press release | GlobeNewswire | — | +0.00% | |
| Form N-CEN DAXOR CORP For: Dec 31 | SEC filing · Form N-CEN | SEC EDGAR | — | +0.00% | |
| Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress | Press release | GlobeNewswire | — | +0.08% | |
| Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 | Press release | GlobeNewswire | +0.00% | +1.71% | |
| Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders | Press release | GlobeNewswire | +1.74% | -1.74% | |
| Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share | Press release | GlobeNewswire | +1.74% | -1.74% | |
| Form N-CSR DAXOR CORP For: Dec 31 | SEC filing · Form N-CSR | SEC EDGAR | +1.74% | -1.74% | |
| Form NPORT-P DAXOR CORP For: Dec 31 | SEC filing · Form NPORT-P | SEC EDGAR | +1.74% | -1.74% | |
| Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee | Press release | GlobeNewswire | — | -1.72% | |
| Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business | Press release | GlobeNewswire | — | -1.22% | |
| Form 40-8F-2 DAXOR CORP | SEC filing · Form 40-8F-2 | SEC EDGAR | — | -1.22% | |
| Form 8-K DAXOR CORP For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | — | -4.72% | |
| Daxor Corporation Announces $9 Million Registered Direct Offering | Press release | GlobeNewswire | -1.13% | +4.92% | |
| Form 8-K DAXOR CORP For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +4.92% | |
| Form EFFECT DAXOR CORP | SEC filing · Form EFFECT | SEC EDGAR | — | +2.28% | |
| Form N-2/A DAXOR CORP | SEC filing · Form N-2 | SEC EDGAR | +0.00% | +2.87% | |
| Form N-CEN/A DAXOR CORP For: Dec 31 | SEC filing · Form N-CEN | SEC EDGAR | +0.00% | +2.87% | |
| Form N-CSR/A DAXOR CORP For: Dec 31 | SEC filing · Form N-CSR | SEC EDGAR | +0.00% | +2.87% | |
| Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer | Press release | GlobeNewswire | — | -0.76% | |
| Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit | Press release | GlobeNewswire | +1.61% | +3.20% | |
| Form N-2/A DAXOR CORP | SEC filing · Form N-2 | SEC EDGAR | +1.61% | +3.20% | |
| Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 | Press release | GlobeNewswire | — | -0.08% | |
| Form N-CSR/A DAXOR CORP For: Dec 31 | SEC filing · Form N-CSR | SEC EDGAR | — | +1.48% | |
| Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA | Press release | GlobeNewswire | — | +6.79% | |
| Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting | Press release | GlobeNewswire | -2.10% | +1.95% | |
| Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care | Press release | GlobeNewswire | -3.39% | +6.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DXR section they belong to.
Where else DXR is measured.
DXR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InfuSystems Holdings, Inc. (INFU) | 202 | 0.00% | 50% |
| Regulus Therapeutics Inc. (RGLS) | 201 | +0.26% | 55% |
| The Joint Corp. (JYNT) | 200 | 0.00% | 45% |
| ProPhase Labs, Inc. (PRPH) | 198 | -0.18% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Daxor Corporation - Closed End Fund's median reaction calculated?
Every labeled DXR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 200 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of DXR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DXR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.